About Freenome
Freenome is a biotechnology company focused on revolutionizing cancer detection through its multiomics platform and artificial intelligence (AI). The company aims to detect cancer in its earliest, most treatable stages via a routine blood draw, making screening more accessible for everyone. Their proprietary platform integrates molecular biology, computational biology, and machine learning to analyze various biological signals, including cell-free DNA (cfDNA) methylation patterns, immune cell fragments, and metabolic markers. This multimodal approach is designed to overcome the inherent heterogeneity of cancer, allowing for the identification of subtle cues associated with the disease even in its nascent stages.
For physicians, Freenome’s technology offers the potential for non-invasive, blood-based screening tests for various cancers, including colorectal and lung cancer. The company’s lead product, SimpleScreen™ CRC, is a blood-based screening test for colorectal cancer, which has undergone clinical validation through the PREEMPT CRC Study. Freenome is also developing tests for lung cancer and a broader portfolio of single-cancer and multi-cancer detection tests. Their approach involves rigorous clinical programs to drive the discovery, development, and validation of these early cancer detection tests, with the goal of expanding access to screening and improving patient outcomes.
Focus Areas
Business Intelligence
| Key Investors | Andreessen Horowitz, Verily Life Sciences, Google Ventures, Polaris Partners, Founders Fund, Section 32, Anne Wojcicki, RA Capital Management, Perceptive Advisors, T. Rowe Price Associates, Inc., Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, Janus Henderson Investors, Novartis, Ridgeback Capital Management, Rock Springs Capital, Sands Capital, Soleus Capital Management, ArrowMark Partners, Byers Capital, Eventide Asset Management LLC, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, Suvretta Capital Management, Quest Diagnostics |
| Partnerships | Abbott, Roche, Exact Sciences, Moores Cancer Center at UC San Diego Health, University of California San Francisco, Massachusetts General Hospital, NVIDIA |
| Acquisitions | unknown |
| Technology | Multiomics platform (integrating cell-free DNA, methylation, proteins, cfRNA, autoantibodies, cfDNA fragmentomics, nucleosome footprinting) with advanced computational biology, machine learning, and deep learning models. Cloud-native infrastructure with AI operating system. |
| FDA Clearances | unknown cleared products (estimated) |
What Physicians Need to Know
For physicians, Freenome's blood-based tests like SimpleScreenu2122 CRC offer a convenient and accessible option for cancer screening, potentially increasing patient adherence to screening guidelines. The non-invasive nature of a simple blood draw can overcome barriers associated with traditional screening methods, such as discomfort or logistical challenges. A positive result from SimpleScreenu2122 CRC should be followed by a colonoscopy. The investigational SimpleScreenu2122 Lung test aims to complement current lung cancer screening guidelines by identifying high-risk individuals who would benefit from low-dose CT. Freenome's Personalized Cancer Detection approach combines risk-based screening with indication-specific blood tests, aiming for more individualized and data-driven screening.
Freenome actively partners with healthcare organizations, academic institutions, and biopharma companies to integrate their technology and software platform into clinical care. They collaborate on biomarker development, clinical study design, and population health analytics, including real-world data integration and EMR integration services. Freenome also leverages cloud technologies like Google Cloud for data storage, analytics (BigQuery), and machine learning model deployment (GKE), and has partnered with NVIDIA to accelerate their AI and deep learning initiatives. They have strategic partnerships with companies like Abbott for commercialization in the U.S. and Roche for international markets.
What the Web Says
Freenome is a biotechnology company focused on early cancer detection through blood-based tests, utilizing a multiomics platform and AI/machine learning. The company has received significant funding and is actively conducting clinical trials for its SimpleScreen CRC test, which has shown improved performance in detecting colorectal cancer and precancerous lesions. While employee reviews generally highlight a positive culture and mission, some concerns exist regarding management and compensation.
Overall: MixedStrengths
- Incredible mission focused on saving lives through early cancer detection.
- Positive work culture with passionate and empathetic colleagues.
- Strong emphasis on culture during the interview process.
- Free meals and snacks available for employees.
- Advanced multiomics platform combined with AI/ML for sensitive cancer detection.
- Improved performance of their colorectal cancer screening test in recent studies.
Limitations
- Leadership struggles with communication and decision-making.
- Managers in some departments are perceived as overworking lab techs without meeting compensation or career needs.
- Compensation may be lower than current market rates, with stock options offered after one year.
- Layoffs have occurred, potentially due to disappointing test results and unsustainable spending.
- Some concerns about professionalism among managers.
- The company is clinical-stage and pre-revenue, with an uncertain path to profitability.
Based on reviews from: Comparably, Zippia, SimplyHired, Indeed.com, MedTech Dive, PR Newswire, Nanalyze, Reddit, Bain Capital Life Sciences
Last updated: 2026-08-30
Videos
News, demos, and interviews about Freenome.
Videos load interactively. If none appear, search YouTube for Freenome →
Frequently Asked Questions
Investors
Who's funded Freenome.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]